Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone adjunctive therapy for major depressive disorder
2021-001192-17Phase 3Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Lumateperone adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoint: Change from baseline to Day 43 in MADRS total score. Started Sep 2021; status: completed.
02
Drugs
lumateperone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2021-001192-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001192-17.